Evidence map›Paper›PMID 25745994›Full record

ArticleOncogene2015

Repression of Hox genes by LMP1 in nasopharyngeal carcinoma and modulation of glycolytic pathway genes by HoxC8.

Y Jiang, B Yan, W Lai, Y Shi, D Xiao, J Jia, S Liu, H Li, J Lu, Z Li and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Biomolecules · 2025
    Review
  4. Article
  5. Understanding Metabolic Pathway Rewiring by Oncogenic Gamma Herpesvirus.Journal of microbiology and biotechnology · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 2 countries.

Y JiangCancer Research Institute, Central South University, Changsha, Hunan, China.
B YanCancer Research Institute, Central South University, Changsha, Hunan, China.
W LaiCancer Research Institute, Central South University, Changsha, Hunan, China.
Y ShiCancer Research Institute, Central South University, Changsha, Hunan, China.
D XiaoDepartment of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
J JiaCancer Research Institute, Central South University, Changsha, Hunan, China.
S LiuCenter for Medicine Research, Xiangya Hospital, Central South University, Changsha, Hunan, China.
H LiCancer Research Institute, Central South University, Changsha, Hunan, China.
J LuCancer Research Institute, Central South University, Changsha, Hunan, China.
Z LiCenter for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.
L ChenCancer Research Institute, Central South University, Changsha, Hunan, China.
X ChenCancer Research Institute, Central South University, Changsha, Hunan, China.
L SunCenter for Molecular Medicine, Xiangya Hospital, Central South University, Changsha, China.
K MueggeMouse Cancer Genetics Program, National Cancer Institute, Basic Science Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA.
Y CaoCancer Research Institute, Central South University, Changsha, Hunan, China.
Y TaoCancer Research Institute, Central South University, Changsha, Hunan, China.
Central South University · CNMinistry of Education of the People's Republic of China · CNFrederick National Laboratory for Cancer Research · US

Funding

Epigenetic control during embryogenesisZIABC010014 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MUEGGE, KATHRIN · 2009 to 2025
$18.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) causes human lymphoid malignancies, and the EBV product latent membrane protein 1 (LMP1) has been identified as an oncogene in epithelial carcinomas such as nasopharyngeal carcinoma (NPC). EBV can epigenetically reprogram lymphocyte-specific processes and induce cell immortalization. However, the interplay between LMP1 and the NPC host cell remains largely unknown. Here, we report that LMP1 is important to establish the Hox gene expression signature in NPC cell lines and tumor biopsies. LMP1 induces repression of several Hox genes in part via stalling of RNA polymerase II (RNA Pol II). Pol II stalling can be overcome by irradiation involving the epigenetic regulator TET3. Furthermore, we report that HoxC8, one of the genes silenced by LMP1, has a role in tumor growth. Ectopic expression of HoxC8 inhibits NPC cell growth in vitro and in vivo, modulates glycolysis and regulates the expression of tricarboxylic acid (TCA) cycle-related genes. We propose that viral latency products may repress via stalling key mediators that in turn modulate glycolysis.

Indexed as

Cells, CulturedCitric Acid CycleDioxygenasesDNA MethylationGenes, HomeoboxGlycolysisHomeodomain ProteinsHumansNasopharyngeal NeoplasmsRNA Polymerase IIViral Matrix ProteinsDioxygenasesEBV-associated membrane antigen, Epstein-Barr virusHomeodomain ProteinsHOXC8 protein, humanRNA Polymerase IITET3 protein, humanViral Matrix Proteins

Identifiers

PMID25745994
PMCPMC4564361
OpenAlexW2040291190

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.